AbCellera Biologics Quarterly Balance Sheets Chart
Quarterly
|
Annual
AbCellera Biologics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||
| current assets: | |||||||||||||||||||
| cash and cash equivalents | 92,437,000 | 159,266,000 | 156,325,000 | 126,640,000 | 148,312,000 | 123,572,000 | 133,320,000 | 172,422,000 | 179,747,000 | 193,017,000 | 386,535,000 | 371,973,000 | 790,615,000 | 545,718,000 | 476,142,000 | 517,694,000 | 792,571,000 | 685,795,000 | 594,116,000 |
| marketable securities | 460,641,000 | 446,000,000 | 469,289,000 | 516,499,000 | 522,044,000 | 574,451,000 | 627,265,000 | 613,418,000 | 615,947,000 | 603,478,000 | 499,950,000 | 496,233,000 | 231,652,000 | 240,335,000 | 246,835,000 | 235,785,000 | |||
| total cash, cash equivalents, and marketable securities | 553,078,000 | 605,266,000 | 625,614,000 | 643,139,000 | 670,356,000 | 698,023,000 | 760,585,000 | 785,840,000 | 795,694,000 | 796,495,000 | 886,485,000 | 868,206,000 | 1,022,267,000 | 786,053,000 | 722,977,000 | 753,479,000 | |||
| accounts and accrued receivable | 47,310,000 | 40,005,000 | 33,616,000 | 31,373,000 | 36,143,000 | 34,419,000 | 30,590,000 | 37,446,000 | 45,678,000 | 20,003,000 | 38,593,000 | 105,964,000 | 52,797,000 | 334,403,000 | 160,576,000 | 43,633,000 | |||
| restricted cash | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 | ||||
| other current assets | 116,757,000 | 94,707,000 | 67,140,000 | 43,371,000 | 40,055,000 | 56,506,000 | 55,810,000 | 71,232,000 | 64,363,000 | 99,155,000 | 75,413,000 | 46,499,000 | 43,891,000 | 28,922,000 | 21,247,000 | 6,635,000 | 6,547,000 | 5,745,000 | 5,970,000 |
| total current assets | 742,145,000 | 764,978,000 | 751,370,000 | 742,883,000 | 771,554,000 | 813,948,000 | 871,985,000 | 919,518,000 | 930,735,000 | 940,653,000 | 1,025,491,000 | 1,045,669,000 | 1,143,955,000 | 1,174,378,000 | 929,800,000 | 803,747,000 | 864,002,000 | 907,982,000 | 813,325,000 |
| long-term assets: | |||||||||||||||||||
| property and equipment | 424,020,000 | 347,102,000 | 340,429,000 | 331,263,000 | 318,882,000 | 306,081,000 | 287,696,000 | 277,209,000 | 259,640,000 | 233,187,000 | 217,255,000 | 200,602,000 | 149,178,000 | 122,049,000 | 111,616,000 | 91,584,000 | 87,479,000 | 34,618,000 | 17,923,000 |
| intangible assets | 40,262,000 | 41,192,000 | 42,113,000 | 52,577,000 | 85,661,000 | 118,736,000 | 120,425,000 | 124,076,000 | 126,747,000 | 128,845,000 | 131,502,000 | 142,548,000 | 143,179,000 | 145,785,000 | 148,392,000 | 148,821,000 | 110,223,000 | 112,688,000 | 115,153,000 |
| goodwill | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 47,806,000 | 49,457,000 | 31,500,000 | 31,500,000 | 31,500,000 |
| investments in equity accounted investees | 90,374,000 | 81,567,000 | 82,297,000 | 84,084,000 | 76,064,000 | 71,592,000 | |||||||||||||
| other long-term assets | 57,454,000 | 61,563,000 | 96,538,000 | 134,215,000 | 112,514,000 | 104,933,000 | 94,244,000 | 80,694,000 | 113,446,000 | 89,845,000 | 46,331,000 | 49,066,000 | 43,842,000 | 43,389,000 | 30,642,000 | 31,616,000 | 15,947,000 | 9,548,000 | 8,388,000 |
| total long-term assets | 659,916,000 | 579,230,000 | 609,183,000 | 649,945,000 | 640,927,000 | 649,148,000 | 616,109,000 | 592,672,000 | 606,431,000 | 557,266,000 | 515,416,000 | 506,740,000 | 449,829,000 | 417,911,000 | 388,769,000 | 368,985,000 | 287,854,000 | 220,541,000 | 192,211,000 |
| total assets | 1,402,061,000 | 1,344,208,000 | 1,360,553,000 | 1,392,828,000 | 1,412,481,000 | 1,463,096,000 | 1,488,094,000 | 1,512,190,000 | 1,537,166,000 | 1,497,919,000 | 1,540,907,000 | 1,552,409,000 | 1,593,784,000 | 1,592,289,000 | 1,318,569,000 | 1,172,732,000 | 1,151,856,000 | 1,128,523,000 | 1,005,536,000 |
| liabilities and shareholders' equity | |||||||||||||||||||
| current liabilities: | |||||||||||||||||||
| accounts payable and other current liabilities | 50,074,000 | 47,840,000 | 55,004,000 | 53,773,000 | 43,952,000 | 42,887,000 | |||||||||||||
| contingent consideration payable | 8,771,000 | 8,087,000 | 20,217,000 | 20,027,000 | 51,431,000 | 50,475,000 | 53,929,000 | 54,874,000 | 15,733,000 | 16,054,000 | 25,392,000 | 24,629,000 | 30,623,000 | 35,886,000 | 44,948,000 | 9,614,000 | 9,378,000 | 9,148,000 | |
| deferred revenue | 16,949,000 | 18,785,000 | 13,521,000 | 5,578,000 | 6,401,000 | 10,565,000 | 18,958,000 | 17,508,000 | 8,542,000 | 11,807,000 | 21,612,000 | 6,815,000 | 4,621,000 | 9,190,000 | 7,536,000 | 6,170,000 | 10,568,000 | 11,306,000 | 6,589,000 |
| total current liabilities | 67,023,000 | 75,396,000 | 76,612,000 | 79,568,000 | 70,380,000 | 104,883,000 | 119,013,000 | 110,239,000 | 118,905,000 | 89,591,000 | 118,320,000 | 106,052,000 | 221,140,000 | 213,418,000 | 120,676,000 | 49,549,000 | 69,758,000 | 88,395,000 | 103,490,000 |
| long-term liabilities: | |||||||||||||||||||
| operating lease liability | 137,184,000 | 63,210,000 | 60,743,000 | 66,274,000 | 66,451,000 | 68,079,000 | 71,222,000 | 75,185,000 | 78,079,000 | 77,265,000 | 76,675,000 | 71,591,000 | 32,759,000 | 36,356,000 | 36,413,000 | 27,264,000 | 31,020,000 | 16,973,000 | 3,715,000 |
| deferred government contributions | 167,532,000 | 157,193,000 | 149,893,000 | 142,046,000 | 124,186,000 | 110,579,000 | 95,915,000 | 84,072,000 | 76,354,000 | ||||||||||
| deferred tax liability | 10,053,000 | 10,053,000 | 10,052,000 | 12,781,000 | 21,737,000 | 30,274,000 | 30,612,000 | 33,178,000 | 33,178,000 | 33,426,000 | 33,178,000 | 34,143,000 | 34,616,000 | 36,804,000 | 37,370,000 | 36,197,000 | 25,510,000 | 26,992,000 | 26,161,000 |
| other long-term liabilities | 1,560,000 | 1,624,000 | 1,469,000 | 1,524,000 | 6,348,000 | 5,735,000 | 5,906,000 | 5,051,000 | 2,333,000 | 2,962,000 | 3,086,000 | 2,857,000 | 2,984,000 | 3,430,000 | 1,733,000 | 1,695,000 | 1,657,000 | 931,000 | 4,422,000 |
| total long-term liabilities | 327,962,000 | 245,830,000 | 227,857,000 | 235,166,000 | 231,133,000 | 228,300,000 | 216,763,000 | 219,176,000 | 223,434,000 | 199,828,000 | 189,310,000 | 196,185,000 | 159,788,000 | 171,364,000 | 172,160,000 | 169,786,000 | 114,419,000 | 83,004,000 | 71,538,000 |
| total liabilities | 394,985,000 | 321,226,000 | 304,469,000 | 314,734,000 | 301,513,000 | 333,183,000 | 335,776,000 | 329,415,000 | 342,339,000 | 289,419,000 | 307,630,000 | 302,237,000 | 380,928,000 | 384,782,000 | 292,836,000 | 219,335,000 | 184,177,000 | 171,399,000 | 175,028,000 |
| commitments and contingencies | |||||||||||||||||||
| shareholders' equity: | |||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2024 and june 30, 2025: 295,757,002 and 298,652,967 shares issued and outstanding at december 31, 2024 and june 30, 2025, respectively | 791,668,000 | ||||||||||||||||||
| additional paid-in capital | 181,483,000 | 168,603,000 | 166,361,000 | 155,354,000 | 140,828,000 | 127,990,000 | 121,052,000 | 109,384,000 | 96,423,000 | 81,630,000 | 74,118,000 | 64,384,000 | 56,001,000 | 44,726,000 | 35,357,000 | 26,945,000 | 21,669,000 | 14,562,000 | 5,919,000 |
| accumulated other comprehensive loss | -2,657,000 | -6,998,000 | -4,378,000 | -1,232,000 | -2,073,000 | -1,816,000 | |||||||||||||
| accumulated earnings | 36,582,000 | 71,309,000 | 116,930,000 | 151,140,000 | 202,247,000 | 239,177,000 | 279,787,000 | 326,937,000 | 355,547,000 | 386,075,000 | 426,185,000 | 456,078,000 | 429,454,000 | 436,239,000 | 267,666,000 | 207,720,000 | 229,100,000 | 231,423,000 | 114,202,000 |
| total shareholders' equity | 1,007,076,000 | 1,022,982,000 | 1,056,084,000 | 1,078,094,000 | 1,110,968,000 | 1,129,913,000 | 1,152,318,000 | 1,182,775,000 | 1,194,827,000 | 1,208,500,000 | 1,233,277,000 | 1,250,172,000 | 1,212,856,000 | 1,207,507,000 | 1,025,733,000 | 953,397,000 | 967,679,000 | 957,124,000 | 830,508,000 |
| total liabilities and shareholders' equity | 1,402,061,000 | 1,344,208,000 | 1,360,553,000 | 1,392,828,000 | 1,412,481,000 | 1,463,096,000 | 1,488,094,000 | 1,512,190,000 | 1,537,166,000 | 1,497,919,000 | 1,540,907,000 | 1,552,409,000 | 1,593,784,000 | 1,592,289,000 | 1,318,569,000 | 1,172,732,000 | 1,151,856,000 | 1,128,523,000 | 1,005,536,000 |
| common shares: no par value, unlimited authorized shares at december 31, 2024 and march 31, 2025: 295,757,002 and 298,355,752 shares issued and outstanding at december 31, 2024 and march 31, 2025, respectively | 790,068,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2023 and december 31, 2024: 290,824,970 and 295,757,002 shares issued and outstanding at december 31, 2023 and december 31, 2024, respectively | 777,171,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2023 and september 30, 2024: 290,824,970 and 295,157,474 shares issued and outstanding at december 31, 2023 and september 30, 2024, respectively | 772,832,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2023 and june 30, 2024: 290,824,970 and 294,665,532 shares issued and outstanding at december 31, 2023 and june 30, 2024, respectively | 769,966,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2023 and march 31, 2024: 290,824,970 and 293,621,312 shares issued and outstanding at december 31, 2023 and march 31, 2024, respectively | 764,562,000 | ||||||||||||||||||
| investments in and loans to equity accounted investees | 65,938,000 | 62,887,000 | 58,792,000 | 57,583,000 | 72,522,000 | 66,718,000 | 65,824,000 | 58,882,000 | 50,313,000 | 47,507,000 | 42,705,000 | 32,187,000 | |||||||
| accounts payable and other liabilities | 49,580,000 | 35,708,000 | 52,395,000 | 31,814,000 | 33,150,000 | 25,866,000 | 24,390,000 | 25,717,000 | 32,017,000 | 24,072,000 | 18,276,000 | 13,287,000 | |||||||
| common shares: no par value, unlimited authorized shares at december 31, 2022 and december 31, 2023: 286,851,595 and 290,824,970 shares issued and outstanding at december 31, 2022 and december 31, 2023, respectively | 753,199,000 | ||||||||||||||||||
| accumulated other comprehensive income | -1,720,000 | -1,391,000 | -717,000 | 576,000 | 787,000 | 280,000 | 644,000 | 2,152,000 | |||||||||||
| accrued royalties payable | 3,094,000 | 3,094,000 | 3,094,000 | 19,347,000 | 17,822,000 | 50,555,000 | 45,364,000 | 22,506,000 | 595,000 | 23,520,000 | 20,010,000 | 27,143,000 | |||||||
| common shares: no par value, unlimited authorized shares at december 31, 2022 and september 30, 2023: 286,851,595 and 289,777,654 shares issued and outstanding at december 31, 2022 and september 30, 2023, respectively | 747,914,000 | ||||||||||||||||||
| accumulated other comprehensive | -1,460,000 | -1,899,000 | -2,021,000 | ||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2022 and june 30, 2023: 286,851,595 and 289,189,469 shares issued and outstanding at december 31, 2022 and june 30, 2023, respectively | 744,756,000 | ||||||||||||||||||
| current portion of contingent consideration payable | 42,876,000 | 44,211,000 | 32,531,000 | 34,252,000 | 27,499,000 | 22,934,000 | 12,122,000 | 11,572,000 | 13,762,000 | 13,411,000 | |||||||||
| deferred grant funding | 45,026,000 | 40,801,000 | |||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2022 and march 31, 2023: 286,851,595 and 288,426,514 shares issued and outstanding at december 31, 2022 and march 31, 2023, respectively | 742,816,000 | ||||||||||||||||||
| income taxes payable | 23,018,000 | 107,322,000 | 105,648,000 | 35,683,000 | 6,590,000 | 5,822,000 | 30,030,000 | 36,152,000 | |||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2021 and 2022: 283,257,104 and 286,851,595 shares issued and outstanding at december 31, 2021 and 2022 respectively | 734,365,000 | ||||||||||||||||||
| subsequent event | |||||||||||||||||||
| deferred revenue and grant funding | 62,202,000 | 64,800,000 | 64,151,000 | 60,758,000 | 59,682,000 | 46,618,000 | 28,730,000 | 25,894,000 | |||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2021 and september 30, 2022: 283,257,104 and 285,761,492 shares issued and outstanding at december 31, 2021 and september 30, 2022, respectively | 730,427,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2021 and june 30, 2022: 283,257,104 and 285,052,302 shares issued and outstanding at december 31, 2021 and june 30, 2022, respectively | 726,825,000 | ||||||||||||||||||
| subsequent events | |||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2021 and march 31, 2022: 283,257,104 and 284,521,181 shares issued and outstanding at december 31, 2021 and march 31, 2022, respectively | 725,755,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2020 and 2021: 269,497,768 and 283,257,104 shares issued and outstanding at december 31, 2020 and 2021 respectively | 722,430,000 | ||||||||||||||||||
| long term assets: | |||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2020 and september 30, 2021: 269,497,768 and 281,151,877 shares issued and outstanding at december 31, 2020 and september 30, 2021 respectively | 718,088,000 | ||||||||||||||||||
| accounts receivable | 2,799,000 | 23,371,000 | 903,000 | ||||||||||||||||
| accrued accounts receivable | 62,085,000 | 193,071,000 | 212,336,000 | ||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2020 and june 30, 2021: 269,497,768 and 276,982,678 shares issued and outstanding at december 31, 2020 and june 30, 2021 respectively | 714,758,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2020 and march 31, 2021: 269,497,768 and 270,925,930 shares issued and outstanding at december 31, 2020 and march 31, 2021 respectively | 711,139,000 | ||||||||||||||||||
| equity investee | 19,247,000 | ||||||||||||||||||
| loans to related parties | |||||||||||||||||||
| accounts payable and accrued liabilities | 20,005,000 | ||||||||||||||||||
| current portion of long-term debt | 190,000 | ||||||||||||||||||
| long-term debt | 2,198,000 | ||||||||||||||||||
| common shares: no par value, unlimited authorized shares at december 31, 2019 and 2020: 151,681,382 and 269,497,768 shares issued and outstanding at december 31, 2019 and 2020 respectively | 710,387,000 | ||||||||||||||||||
| convertible preferred shares unlimited authorized shares at december 31, 2019 and 2020: 2,105,264 and nil issued and outstanding at december 31, 2019 and 2020 respectively |
We provide you with 20 years of balance sheets for AbCellera Biologics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AbCellera Biologics. Explore the full financial landscape of AbCellera Biologics stock with our expertly curated balance sheets.
The information provided in this report about AbCellera Biologics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.